logo-loader

AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”

Last updated: 09:57 30 Mar 2020 BST, First published: 09:13 30 Mar 2020 BST

AstraZeneca - AstraZeneca stops trial early for “overwhelming efficacy”

AstraZeneca PLC (LON:AZN) has stopped a late-stage trial of its chronic kidney disease treatment as it showed “overwhelming efficacy”.

An independent committee advised the FTSE 100-listed company to halt the studies for Farxiga, which is already under review to treat patients with heart failure.

READ: AstraZeneca posts negative results for late-stage bladder cancer treatment

AstraZeneca will now initiate discussions with global health authorities regarding early regulatory submissions.

In a note to clients, analysts at Shore Capital said they expect Farxiga to generate US$3bn by 2024.

In a separate announcement, the pharma giant also said that its Imfinzi drug has been approved in the US as a first-line treatment for extensive-stage small cell lung cancer, in combination with chemotherapies.

Imfinzi, which has already been approved for other types of cancer, is expected to generate sales of US$2bn this year and grow to US$4bn by 2024.

AstraZeneca shares rose 1% to 6,858p on Monday morning.

-- Adds analyst comment --

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

3 hours ago